KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $16.3 million.

  • GoodRx Holdings' Capital Expenditures rose 514.36% to $16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.4 million, marking a year-over-year increase of 1122.17%. This contributed to the annual value of $69.1 million for FY2024, which is 2628.51% up from last year.
  • Per GoodRx Holdings' latest filing, its Capital Expenditures stood at $16.3 million for Q3 2025, which was up 514.36% from $17.9 million recorded in Q2 2025.
  • In the past 5 years, GoodRx Holdings' Capital Expenditures registered a high of $21.7 million during Q1 2025, and its lowest value of $6.6 million during Q2 2021.
  • In the last 5 years, GoodRx Holdings' Capital Expenditures had a median value of $14.1 million in 2023 and averaged $13.7 million.
  • As far as peak fluctuations go, GoodRx Holdings' Capital Expenditures skyrocketed by 15539.7% in 2021, and later crashed by 1768.16% in 2023.
  • GoodRx Holdings' Capital Expenditures (Quarter) stood at $8.5 million in 2021, then skyrocketed by 79.13% to $15.1 million in 2022, then fell by 17.68% to $12.5 million in 2023, then surged by 32.25% to $16.5 million in 2024, then fell by 1.4% to $16.3 million in 2025.
  • Its last three reported values are $16.3 million in Q3 2025, $17.9 million for Q2 2025, and $21.7 million during Q1 2025.